share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  11/06 07:02

Moomoo AI 已提取核心信息

On November 5, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company, announced the entry into a warrant exercise inducement offer with certain holders of its existing warrants. The agreement involves holders of Series A, B, A-1, and B-1 Common Stock purchase warrants, which were previously issued in December 2023 and August 2024. Under the inducement offer, the holders agreed to exercise their existing warrants for cash at a reduced price of $2.06 per share. In return, ZyVersa will issue new warrants allowing holders to purchase double the number of shares at the same reduced price, with a five-year term from the initial exercise date. The transaction is expected to generate approximately $1.7 million in gross proceeds for ZyVersa, which will be used for working capital and...Show More
On November 5, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company, announced the entry into a warrant exercise inducement offer with certain holders of its existing warrants. The agreement involves holders of Series A, B, A-1, and B-1 Common Stock purchase warrants, which were previously issued in December 2023 and August 2024. Under the inducement offer, the holders agreed to exercise their existing warrants for cash at a reduced price of $2.06 per share. In return, ZyVersa will issue new warrants allowing holders to purchase double the number of shares at the same reduced price, with a five-year term from the initial exercise date. The transaction is expected to generate approximately $1.7 million in gross proceeds for ZyVersa, which will be used for working capital and general corporate purposes. The issuance of shares upon exercise of the new warrants is contingent on stockholder approval, with a meeting to be convened within 120 days post-transaction completion. ZyVersa has also committed to filing a registration statement to facilitate the resale of the shares from the new warrants. Additionally, the company has entered into a financial advisory agreement with A.G.P./Alliance Global Partners, for which it will pay a $110,000 fee and up to $10,000 for non-accountable expenses.
2024年11月5日,生物医药公司ZyVersa Therapeutics, Inc.宣布与持有其现有认股权证的特定持有人达成了认股权证行权诱因要约。该协议涉及在2023年12月和2024年8月先前发行的A亿、A-1和b-1普通股认股权证的持有人。根据诱因要约,持有人同意以每股2.06美元的折扣价格现金行使其现有认股权证。作为回报,ZyVersa将发行新的认股权证,允许持有人以相同的折扣价格购买双倍股数,有效期为自初次行使之日起的五年。该交易预计将为ZyVersa带来大约170万美元的总收入,这将用于营运资金和一般企业用途。在新认股权证行使股份时的股票发行取决于股东批准,将在交易完成后的120天内召开股东大会。ZyVersa还承诺提交注册声明,以促进新认股权证的股份转售。此外,公司还与A.G.P./Alliance Global Partners签订了财务咨询协议,据此支付11万美元的费用和高达1万美元的不可核算费用。
2024年11月5日,生物医药公司ZyVersa Therapeutics, Inc.宣布与持有其现有认股权证的特定持有人达成了认股权证行权诱因要约。该协议涉及在2023年12月和2024年8月先前发行的A亿、A-1和b-1普通股认股权证的持有人。根据诱因要约,持有人同意以每股2.06美元的折扣价格现金行使其现有认股权证。作为回报,ZyVersa将发行新的认股权证,允许持有人以相同的折扣价格购买双倍股数,有效期为自初次行使之日起的五年。该交易预计将为ZyVersa带来大约170万美元的总收入,这将用于营运资金和一般企业用途。在新认股权证行使股份时的股票发行取决于股东批准,将在交易完成后的120天内召开股东大会。ZyVersa还承诺提交注册声明,以促进新认股权证的股份转售。此外,公司还与A.G.P./Alliance Global Partners签订了财务咨询协议,据此支付11万美元的费用和高达1万美元的不可核算费用。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息